Google_______________
GlaxoSmithKline Offers Savings Program for Patients Purchasing Fosamprenavir

In a letter to HIV treatment advocates, Michael Joyner, Director of HIV Communications and Advocacy at GlaxoSmithKline (GSK), announced a 2-year GSK program that will provide a cash benefit to patients using the protease inhibitor fosamprenavir (Lexiva).

The program is designed to reduce out-of-pocket costs for patients using fosamprenavir as part of their anti-HIV drug regimen.

Following is the text of the GSK letter to community treatment advocates:

"GlaxoSmithKline is pleased to introduce a savings program designed to help improve patients' adherence to their drug regimens. This program helps reduce out-of-pocket prescription costs for individuals beginning treatment with Lexiva, or who are currently on an HIV treatment regimen that includes Lexiva.

"Individuals eligible for the program include patients who are paying out-of-pocket costs and whose prescriptions are not covered by Medicaid, Medicare, ADAP [AIDS Drug Assistance Programs], or any other federal or state assistance program. Massachusetts residents are eligible only if their prescription for Lexiva is not covered by any insurance or assistance program.

"Patients eligible for the program will receive a Patient Support Card from their healthcare provider along with their prescription for Lexiva. These Patient Support Cards cover out-of-pocket expenses up to $50 for each use and are valid for 24 months following activation.

"We encourage patients to talk to their doctor about the Patient Support Card if it is determined that Lexiva is the right medication for them as a component of their overall HIV regimen."

Joyner added that healthcare providers should contact their GSK HIV sales representative about obtaining cards for eligible patients.

02/13/07

Source
GlaxoSmithKline


 

 

Index of All HIV and AIDS
Articles by Topic ( A to Z)

FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase (amprenavir)
Aptivus (tipranavir)
Crixivan (indinavir)
Fortovase (saquinavir soft gel)
Invirase (saquinavir hard gel)
Kaletra (lopinavir/ritronavir)
Lexiva
(Fosamprenavir)
Norvir (ritonavir)
Prezista
(darunavir)
Reyataz (atazanavir)
Viracept
(nelfinavir)

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir (AZT+ 3TC)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Hivid (zalcitabine; ddC)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (Tenofovir / Emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)

non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor (delavirdine)

Sustiva (efavirenz)
Viramune (nevirapine)

Entry Inhibitors
Fuzeon (enfuvirtide; T-20)

Fixed-dose Combinations
Atripla
(efavirenz + emtricitabine + tenofovir)
Combivir
(retrovir + lamivudine)

Trizivir
(abacavir + zidovudine + lamivudine)
Truvada
(tenofovir + emtricitabine)